Medical Condition News

RSS

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

Proton beam radiation therapy shows encouraging results for patients with locally advanced sinonasal malignancies, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Schizophrenia: Insight into late development of symptoms

In reports of two new studies, researchers led by Johns Hopkins say they have identified the mechanisms rooted in two anatomical brain abnormalities that may explain the onset of schizophrenia and the reason symptoms don't develop until young adulthood. Both types of anatomical glitches are influenced by a gene known as DISC1, whose mutant form was first identified in a Scottish family with a strong history of schizophrenia and related mental disorders. The findings could lead to new ways to treat, prevent or modify the disorder or its symptoms.

26 Feb 2010

Heel pain continues to be the most common reason patients seek care, say foot and ankle surgeons

If you are suffering from heel pain, you're not alone. According to foot and ankle surgeons attending the 68th Annual Scientific Conference of the American College of Foot and Ankle Surgeons in Las Vegas this week, heel pain continues to be the most common reason patients seek care. Surgeons advise the best defense to keeping pain in control is early treatment.

26 Feb 2010

Surgeons perform nation's first incision-free myotomy procedure to treat achalasia

Surgeons at UC San Diego Medical Center have performed the nation's first incision-free myotomy, a procedure to treat achalasia, a distressing disorder which causes difficulty swallowing, regurgitation and chest pain. The innovative surgery, performed through the mouth, is the most recent in a series of groundbreaking clinical trial surgeries being evaluated by the UCSD Center for the Future of Surgery.

26 Feb 2010

CPF to partner with ATS to fund Pulmonary Fibrosis research

The Coalition for Pulmonary Fibrosis and the American Thoracic Society, the world's leading professional organization for pulmonary, critical care and sleep physicians, today announced that the CPF will again partner with the ATS to fund Pulmonary Fibrosis (PF) research.

26 Feb 2010

NORD lauds FDA's establishment of new position within CDER

Peter L. Saltonstall, president and CEO of the National Organization for Rare Disorders (NORD), today said the Food and Drug Administration's (FDA) announcement that it has created a new position—Associate Director for Rare Diseases—in the agency's Center for Drug Evaluation and Research's (CDER) Office of New Drugs (OND) represents an important advance for patients with rare diseases.

26 Feb 2010

New dietary supplement blocks triggering mechanism causing breast cell mutations

Every 13 minutes a woman loses her battle with breast cancer and in 2009 alone more than 27,000 men died from prostate cancer. These powerful statistics continue to fuel research and new developments. With tens of millions of dollars in financial support from the National Cancer Institute and the U.S. Department of Defense, scientists have identified when estrogen metabolism is out of balance it can start the process leading to breast cell mutations.

26 Feb 2010

Exergames improve mood and mental health-related quality of life in seniors with SSD

Research at the Sam and Rose Stein Institute for Research on Aging at the University of California, San Diego School of Medicine suggests a novel route to improving the symptoms of subsyndromal depression (SSD) in seniors through the regular use of "exergames" - entertaining video games that combine game play with exercise. In a pilot study, the researchers found that use of exergames significantly improved mood and mental health-related quality of life in older adults with SSD.

26 Feb 2010

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Using an accelerated, shorter course of radiation therapy for patients with advanced head and neck cancer allows doctors to reduce the amount of chemotherapy, thus reducing toxicity, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

26 Feb 2010

Misperceptions about risk, symptoms and lethality of lung cancer increase mortality rates for lung cancer

A new analysis published this week in the journal Cancer indicates that misperceptions about risk, symptoms and the lethality of lung cancer may play a role in the disproportionately higher incidence and mortality rates for lung cancer among African Americans.

26 Feb 2010

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

A recent multi-center study has confirmed earlier study results that 400 mg/day of lacosamide provides a good balance of efficacy and tolerability for patients with uncontrolled partial-onset seizures (POS), and doses of 600mg/day may provide additional benefit for some patients.

26 Feb 2010

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on HAE

Hereditary angioedema (HAE) can be difficult to accurately diagnose and equally difficult to effectively treat. To overcome the many obstacles to managing the care of patients with HAE, healthcare professionals must be aware of the most up-to-date clinical data regarding HAE diagnosis and treatment.

26 Feb 2010

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

Resverlogix Corp. announced today that it has officially activated the first site for the ASSURE 1 trial and commenced enrollment of patients for dosing of RVX-208. ASSURE 1 is the second Resverlogix Phase 2 clinical trial, led by Cleveland Clinic. This trial will examine RVX-208, Resverlogix's oral small molecule therapy for the treatment of atherosclerosis, in patients with acute coronary syndrome (ACS). This preparatory acute coronary syndrome study will ensure that 50 percent of the enrolled patients receive the IVUS (intravascular ultrasound) assessment.

26 Feb 2010

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

Vanda Pharmaceuticals Inc. announced today that the U.S. Patent and Trademark Office has issued a notice of allowance for its patent application of a microsphere, long-acting injectable formulation of its antipsychotic product, Fanapt™ (iloperidone). When issued, this U.S. patent will expire on October 30, 2022, and in addition, the U.S. Patent and Trademark Office has granted a patent term adjustment of 300 days, leading to an effective expiration date of August 26, 2023.

26 Feb 2010

New fatigue rating scale predicts increased risk of heart attack in dialysis patients

For dialysis patients, high scores on a new fatigue rating scale predict an increased risk of heart attack or other cardiovascular events, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.

25 Feb 2010

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

BioMedix Vascular Solutions, Inc. announced today that the company has partnered with Howard University Hospital, Department of Surgery to participate in a Community Health Project and Demonstration focused on diagnosing and treating the potentially life-threatening condition called Peripheral Arterial Disease (PAD).

25 Feb 2010

Lawsuit alleges Medtronic illegally marketed stent device for unapproved use

A complaint filed in federal court last week "alleges Medtronic Inc. illegally marketed a relatively obscure medical device called a biliary stent in ways not approved by federal regulators," The (Minneapolis-St. Paul) Star Tribune reports.

25 Feb 2010

FDA sets new PDUFA action date for exenatide once weekly NDA

Amylin Pharmaceuticals, Inc., Eli Lilly and Company and Alkermes, Inc. today confirmed that the U.S. Food and Drug Administration (FDA) has set a new Prescription Drug User Fee Act (PDUFA) action date of March 12 for its review of the exenatide once weekly new drug application (NDA).

25 Feb 2010

Greater access to rehabilitation after TIA needed to prevent future strokes

Transient Ischemic Attacks (TIA) are often called "mini strokes" for good reasons -- the short-term symptoms can mimic a stroke and up to 10 percent of first-time sufferers often experience full-blown strokes within as little as 90 days. Despite the well-known statistics, no post-TIA regimen exists to help prevent future strokes -- but this might be changing.

25 Feb 2010

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

Interventional radiologists-minimally invasive specialists-will share scientific advances and new discoveries in treating a host of diseases at the Society of Interventional Radiology's 35th Annual Scientific Meeting March 13󈝾 at the Tampa Convention Center, Tampa, Fla. This year's meeting theme is "IR Innovation"-one that celebrates the remarkable inventiveness of interventional radiologists.

25 Feb 2010

Medical Condition News

Locally advanced sinonasal malignancies: Proton beam radiation therapy promising

Schizophrenia: Insight into late development of symptoms

Heel pain continues to be the most common reason patients seek care, say foot and ankle surgeons

Surgeons perform nation's first incision-free myotomy procedure to treat achalasia

CPF to partner with ATS to fund Pulmonary Fibrosis research

NORD lauds FDA's establishment of new position within CDER

New dietary supplement blocks triggering mechanism causing breast cell mutations

Exergames improve mood and mental health-related quality of life in seniors with SSD

Accelerated radiation therapy helps reduce amount of chemotherapy in advanced head and neck cancer patients

Misperceptions about risk, symptoms and lethality of lung cancer increase mortality rates for lung cancer

Study confirms efficacy and tolerability of lacosamide for uncontrolled POS

RMEI, PIM jointly sponsor complimentary continuing education virtual lecture on HAE

Resverlogix commences enrollment in RVX-208 Phase 2 clinical trial for atherosclerosis in ACS patients

USPTO issues notice of allowance for Vanda Pharmaceuticals' Fanapt long-acting injectable formulation

New fatigue rating scale predicts increased risk of heart attack in dialysis patients

BioMedix Vascular Solutions, Howard University Hospital to participate in Community Health Project and Demonstration

Lawsuit alleges Medtronic illegally marketed stent device for unapproved use

FDA sets new PDUFA action date for exenatide once weekly NDA

Greater access to rehabilitation after TIA needed to prevent future strokes

Interventional radiologists to highlight scientific advances, new discoveries at 35th Annual Scientific Meeting

How can microdialysis benefit drug development

Global and Local Efforts to Take Action Against Hepatitis

Addressing Important Cardiac Biology Questions with Shotgun Top-Down Proteomics

Latest News